Compounds > pnu 151807
Page last updated: 2024-11-11

pnu 151807

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9853489
CHEMBL ID556031
SCHEMBL ID3454493
MeSH IDM0305933

Synonyms (6)

Synonym
CHEMBL556031
pnu-151807
3-[1-methyl-4[1-methyl-4[1-methyl-4-[1-methyl-4-(alpha-bromoacrylamido)pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine hydrochloride
YFLFXMYCMOBTCC-UHFFFAOYSA-N
3-[1-methyl-4[1-methyl-4[1-methyl-4-[1-methyl-4(alpha-bromoacrylamido)pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propionamidine hydrochloride
SCHEMBL3454493
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID101068Inhibition of growth in L1210 leukemia cells resistant to doxorubicin(DX).2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A.
AID98941In vivo optimal dose for its cytotoxicity against L1210 murine leukemia cells2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID101067Compound was tested against L1210 leukemia cells resistant to Tallimustine for 50% inhibitory concentration; Not determined2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A.
AID98540In vitro test for cytotoxicity against L1210 murine leukemia cells2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID235114Ratio between IC50 value on resistant cells and sensitive cells2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A.
AID99286In vivo median survival time of treated vs untreated mice x 100 against murine L1210 leukemia cells after ip treatment on day 1 after tumor iv transplant2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A.
AID133489In vivo antileukemic activity was determined on L1210 leukemia cell in mice (O.D.=optimal (non-toxic) dose 2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Cytotoxic alpha-bromoacrylic derivatives of distamycin analogues modified at the amidino moiety.
AID101073In vitro antitumor activity evaluated against L1210 murine leukemia cell line2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A.
AID99287In vivo median survival time of treated vs untreated mice x 100 against murine L1210 leukemia cells after iv treatment on day 1 after tumor iv transplant2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A.
AID137382Median survival time of treated vs untreated was reported2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID136567In vivo antileukemic activity against L1210 murine leukemia in mice after iv administration of compound expressed as T/C ie median survival time of treated versus untreated mice (10)2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Cytotoxic halogenoacrylic derivatives of distamycin A.
AID101234In vivo optimal nontoxic dose against murine L1210 leukemia cells after i.v. administration day 1 after tumor i.p. inoculation.2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A.
AID98577Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID98329In vitro cytotoxicity against L1210 murine leukemia cells after 48 hr of continuous exposure2002Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11
Cytotoxic alpha-bromoacrylic derivatives of low molecular weight.
AID45126In vitro apparent permeability (Paap*10e-6) coefficient after 120 min incubation of Caco-2 cells in presence of compound2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID45267Caco-2 cell permeability coefficient was determined after 120 min of incubation2002Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11
Cytotoxic alpha-bromoacrylic derivatives of low molecular weight.
AID101232In vivo optimal nontoxic dose against murine L1210 leukemia cells after ip treatment on day 1 after tumor ip transplant2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Synthesis and antitumor activity of new benzoheterocyclic derivatives of distamycin A.
AID136581In vivo antileukemic activity was determined in mice infected with L1210 leukemia cell after intravenous of treated versus untreated mice 10)2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Cytotoxic alpha-bromoacrylic derivatives of distamycin analogues modified at the amidino moiety.
AID97133Ratio between IC50 values on L1210 and L1210/L-PAM cells2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID98134In vitro inhibitory activity against L1210 cell2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Cytotoxic alpha-bromoacrylic derivatives of distamycin analogues modified at the amidino moiety.
AID133487In vivo antileukemic activity against L1210 murine leukemia cell after intravenous administration in mice expressed as optimal (non toxic) dose2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Cytotoxic halogenoacrylic derivatives of distamycin A.
AID137373Median survival time of mice injected with L1210 cells intravenously versus untreated mice at an optimal (non toxic) dose of 1.56 mg/kg2002Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11
Cytotoxic alpha-bromoacrylic derivatives of low molecular weight.
AID98578Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells,(cells resistant to melphalan (L-PAM)2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
AID100655In vitro cytotoxicity was measured after 48 hr of exposure against L1210 murine leukemia cells2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Cytotoxic halogenoacrylic derivatives of distamycin A.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
stallimycin
[no description available]		210
u 77779
bizelesin: structure given in first source		2.0210
tallimustine
tallimustine: structure given in first source		2.0210
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		2.0210L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
carzelesin
carzelesin: a cyclopropylpyrroloindole analog of U 73975; longer lasting than U 77779; structure in first source		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		02.0110